Plus Therapeutics (PSTV) said Monday that data from an early-stage trial using Reyobiq to treat leptomeningeal metastases, a kind of cancer, is "feasible, has a manageable safety profile, and shows a promising efficacy signal."
The study involved 29 patients in six cohorts who received a different dosage in each one, the company said.
The company said that the trial data showed a radiographic and clinical response rate of 76% and 87%, respectively, through day 112, that CSF tumor cell enumeration assays had a maximum reduction over baseline of 100% at day 28, and that five of the seven patients with a TCE response of more than 80% survived for at least one year.
Shares of Plus Therapeutics were down 3% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。